Apixaban

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Apixaban and aspirin offered similar protection against major ischemic and hemorrhagic events among people with cancer history and cryptogenic stroke.

Anticoagulation with apixaban after cryptogenic stroke with evidence of atrial cardiopathy and no atrial fibrillation did not prevent recurrent stroke compared with aspirin, researchers reported.

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

PHILADELPHIA — In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke but increased risk for bleeding compared with aspirin, according to the results of the ARTESIA trial.

PHILADELPHIA — Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation are safe in most high-risk populations, a speaker said during the Heart in Diabetes CME Conference.

AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.

Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported.